Is Prime Medicine, Inc. (PRME) a Buy, Sell, or Hold?
Prime Medicine, Inc.
NASDAQ:PRME
$3.47 USD
-$0.04 (-1.28%)
- Volume
- 3.58M
- Average Volume
- 3.06M
- Market Capitalization
- $626.74M
- P/E Ratio
- -2.74
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $6.94
- Year Low
- $2.67
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.80
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Allan Reine |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PRME |
| CUSIP | 74168J101 |
| CIK | 0001894562 |
| Web | https://www.primemedicine.com |
| Phone | 617-564-0013 |
| Currency | USD |
| Employees | 146 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.49 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.80 |
| Quick Ratio | 3.80 |
| Cash Ratio | 1.77 |
Sales & Book Value
| Annual Sales | $4.63M |
| Price / Sales | 155.37 |
| Cash Flow | -0.90 |
| Price / Cash Flow | -3.95 |
| Price / Book | 8.01 |
Price Target and Rating
| Average Stock Price Forecast | $7.00 |
| High Stock Price Forecast | $8.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -50.43% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.35 |
| Trailing P/E Ratio | -2.74 |
| PEG Ratio | -0.10 |
| P/E Growth | -0.10 |
| Net Income | $-201.14M |
| Net Margin | -4917.55% |
| Pretax Margin | -4917.55% |
| Return on Equity | -188.82% |
| Return on Assets | -67.31% |
Financials Score
| AltmanZ Score | -4.48 |
| Piotroski Score | 2.00 |
| Working Capital | 101.6M |
| Total Assets | 294.73M |
| Ebit | -198.37M |
| Market Cap | 642.1M |
| Total Liabilities | 218.03M |
Poll Results
About Prime Medicine, Inc. (NASDAQ:PRME) Stock
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts. ...
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
2026-07-09 10:22:58
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
2026-07-08 13:29:41
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
2026-07-08 08:00:00
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties' 2019 Collaboration and License Agreement (Agreement).
2026-06-22 08:00:00
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359's potential to address unmet need in p47 phox -deficient CGD -- -- Designation enables early and intensive FDA engagement, and provides eligibility for rolling and priority Biologics License Application review -- -- PM359 now holds RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations -- CAMBRIDGE, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, an investigational autologous Prime Edited hematopoietic stem cell therapy for the treatment of p47phox-deficient chronic granulomatous disease (CGD).
2026-06-18 08:00:00
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-15 16:10:02
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DNA technology to search and replace genetic mutations at their source.
Prime Medicine's Prime Editing Is Worth The Risk
2026-06-13 04:51:30
Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: Prime Editing. PM359 was essentially their most advanced application of Prime Editing, even though CGD is a relatively niche market because it's a rare disease. Management decided to deprioritize PM359, and instead, it's now focused on applying Prime Editing towards larger TAMs like Wilson Disease and AATD.
Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors
2026-06-12 18:30:00
MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise minimum gross proceeds of $1,200,000 and maximum gross proceeds of $2,200,000 (the “Unit Offering”).
Frequently Asked Questions
-
What is the current Prime Medicine, Inc. (PRME) stock price?
-
Prime Medicine, Inc.(NASDAQ:PRME) stock price is $3.47 in the last trading session. During the trading session, PRME stock reached the peak price of $6.94 while $2.67 was the lowest point it dropped to. The percentage change in PRME stock occurred in the recent session was --1.28% while the dollar amount for the price change in PRME stock was -$-0.04.
-
PRME's industry and sector of operation?
-
The NASDAQ listed PRME is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PRME?
-
Andrew Anzalone | Co-Founder & Head of Platform
Ryan E. Brown | Chief Legal Officer
Allan Reine | Chief Executive Officer & Director
David R. Liu | Co-Founder & Member of Scientific Advisory Board
Keith Michael Gottesdiener | Consultant -
How many employees does PRME have?
-
Number of PRME employees currently stands at 146. PRME operates from 21 Erie Street, Cambridge, MA 02139, US.
-
Link for PRME official website?
-
Official Website of PRME is: https://www.primemedicine.com
-
How do I contact PRME?
-
PRME could be contacted at phone #617-564-0013 and can also be accessed through its website. PRME operates from 21 Erie Street, Cambridge, MA 02139, US.
-
How many shares of PRME are traded daily?
-
The average number of PRME shares traded daily for last 3 months was 3.06M.
-
What is the market cap of PRME currently?
-
The market value of PRME currently stands at $626.74M with its latest stock price at $3.47